BioSpace News Archive

Mercury Bio, a Santa Fe, NM-based biotech company working in the area of targeted molecular drug delivery, achieved two financial milestones in the first half of August as it concluded a $2M seed funding round, and welcomed John Tomes as Finance Director for the growing company.

This year marks the fifth anniversary of the Gilead COMPASS Initiative®, a 10-year, more than $100 million commitment to addressing the HIV epidemic in the Southern United States.

IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that the company’s interim report for the period January-June 2023, has been published.

Asieris Pharmaceuticals announced that the National Medical Products Administration has approved the Investigational Drug application for its oral drug APL-1401 for the treatment of moderately-to-severely active ulcerative colitis.The IND application had previously been approved by the U.S. Food and Drug Administration.

BioInvent International “In the quarter, we had impressive early signals of efficacy in the Phase 1/2 trial of our lead drug candidate, the novel anti-FcgRIIB antibody BI-1206, in combination with rituximab in non-Hodgkin’s lymphoma.

SparingVision announced positive initial safety data from the Phase I/II clinical trial of SPVN06, the Company’s lead gene-agnostic gene therapy for the treatment of retinitis pigmentosa.

Voyager Therapeutics, Inc., a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, announced that management will participate in the following investor conferences.

Kamada Ltd. announced shareholder approval and planned closing of the previously announced $60 million private placement with FIMI Opportunity Funds, the leading private equity firm in Israel and a large existing Kamada shareholder.

Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in complement, announced that the company will participate in the following investor conferences.

argenx announced that members of management will participate in several upcoming investor conferences in September: